What You Should Know:

你应该知道的：

PathAI Diagnostics, formerly Poplar Healthcare, a leading laboratory services company, today unveiled the world’s first AI-assisted laboratory-developed test for metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH).MASLD and MASH are posing an escalating healthcare challenge, affecting millions of individuals worldwide – as many as 37.8% of the global adult population suffers from some form of MASLD, a potential precursor to severe conditions such as cirrhosis and liver cancer. .

PathAI Diagnostics，前身为领先的实验室服务公司Poplar Healthcare，今天推出了世界上第一个由AI辅助实验室开发的代谢功能障碍相关脂肪性肝病（MASLD）和代谢功能障碍相关脂肪性肝炎（MASH）测试.MASLD和MASH正在构成不断升级的医疗保健挑战，影响全世界数百万人-多达37.8%的全球成年人口患有某种形式的MASLD，这是肝硬化和肝癌等严重疾病的潜在前兆。 .

AI-Driven Tests for Improving MASLD/MASH Detection

AI驱动的测试，用于改善MASLD/MASH检测

While the gold standard for MASLD/MASH scoring is liver biopsy, the scoring provided by pathologists can exhibit variability. In fact, there can be as much as a 30% disagreement in MASH diagnosis between pathologists, and intra-observer variability can reach up to 41% for the same case. Accurate scoring and staging are paramount, as each fibrosis stage corresponds to approximately a two-fold increase in liver-related mortality.

虽然MASLD/MASH评分的金标准是肝活检，但病理学家提供的评分可能表现出变异性。事实上，病理学家之间在醪液诊断方面可能存在多达30%的分歧，同一病例的观察者内变异性可达41%。准确的评分和分期是至关重要的，因为每个纤维化阶段相当于肝脏相关死亡率增加约两倍。

In response to this need, PathAI Diagnostics today announced AI.Dx MASH, a laboratory-developed test which provides AI-assisted histologic scoring that supports expert pathologists with enhanced insights for liver biopsy reporting..

为了满足这一需求，PathAI Diagnostics today宣布了AI.Dx MASH，这是一项实验室开发的测试，可提供AI辅助的组织学评分，为专家病理学家提供肝脏活检报告的更深入见解。。

In order to better tackle this growing issue, PathAI Diagnostics developed AI.Dx MASH, a laboratory developed test, which provides AI-assisted histologic scoring that supports expert pathologists with enhanced insights for liver biopsy reporting. “We are excited to bring the world’s first AI-assisted Laboratory Developed Test for MASH to market,” said Jim Sweeney, President of PathAI Diagnostics.

为了更好地解决这个日益增长的问题，PathAI Diagnostics开发了AI.Dx MASH，这是一项实验室开发的测试，可提供AI辅助的组织学评分，支持专家病理学家对肝活检报告提供更深入的见解。PathAI Diagnostics总裁Jim Sweeney说：“我们很高兴将世界上第一个人工智能辅助实验室开发的醪液测试推向市场。”。

“The tool uses our deep expertise in AI-powered pathology coupled with our world-class diagnostics laboratory to improve patient outcomes through AI-assisted histologic scoring for MASH.”.

“该工具利用我们在人工智能病理学方面的丰富专业知识，加上我们世界级的诊断实验室，通过人工智能辅助的组织学评分来改善患者的预后。”。

This groundbreaking tool utilizes an AI algorithm that has been proven to significantly reduce inter- and intra-operator variability in CRN scoring. Moreover, AI.Dx MASH reports include image overlays and quantitation, offering a comprehensive view of steatosis, lobular inflammation, hepatocyte ballooning, and fibrosis, thus facilitating more accurate diagnosis and staging.8-11.

这个开创性的工具利用了AI算法，该算法已被证明可以显着降低CRN评分中操作员之间和操作员之间的差异。此外，AI.Dx MASH报告包括图像叠加和定量，提供脂肪变性，小叶炎症，肝细胞气球样变和纤维化的全面视图，从而促进更准确的诊断和分期。